Filgotinib Maleate not checked

Eisai

FollowEvery change as it happens, and a Monday email
Stage
in Japan
Next date
Phase 4 trial completes
Trials
9 active
13 in total · 11 in the EU
Targets
—
None known yet

What this is

How it works
Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.JAK inhibitor Named by hand
Tested for
Ulcerative Colitis
Main trialPhase 4
“The primary purpose of this study is to evaluate the efficacy of filgotinib in establishing clinical remission at Week 10 or 22.”In the company’s words, NCT06964113 on ClinicalTrials.gov
Other names
Jyseleca

Other drugs for Ulcerative Colitis

All 79 drugs for Ulcerative Colitis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials13

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 30 Nov 2027 A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
Phase 4Completed 21 Jan 2026 A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis
Phase 2Not authorised not given Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID)
Phase 2Authorised not given Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID)
Phase 4Authorised not given JAK inhibitor dose TAPering strategy study in low disease activity rheumatoid arthritis patients
Phase 4Ended not given PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, open-label, randomized controlled trial comparing usual care with a tailor-made approach
Phase 3Authorised not given FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial
Phase 3/4Authorised not given RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASALAZINE + HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE OR LEFLUNOMIDE (The BIO-3 trial)
Phase 4Authorised not given Filgotinib bridging in newly diagnosed rheumatoid arthritis patients (FAST RA trial); A pragmatic randomized controlled non-inferiority low intervention clinical trial
Phase 4Ended not given The effect of Janus Kinase inhibitors on the heart in Rheumatoid Arthrtis
Phase 4Authorised not given REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases
Phase 4Authorised not given Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference
Phase 4Authorised not given STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Filgotinib Maleate

Following is part of Solo: you see every change to Filgotinib Maleate the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in